43.82
-2.82%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Xiamen Amoytop Biotech Co
Its shares trade on Shanghai under the ticker 688278.SS. It has been listed since 17 January 2020. In the fiscal year to 31 December 2025, it reported revenue of CN¥3.70bn and net income of CN¥1.04bn. At that date it held total assets of CN¥4.37bn and shareholders' equity of CN¥3.01bn.
Xiamen Amoytop Biotech Co. Ltd. engages in the research and development of genetic engineering technology. The company is headquartered in Xiamen, Fujian. The company went IPO on 2020-01-17. The firm's main research and development direction is immune-related cytokine drugs, focusing on systemic immune solutions based on cytokine drugs, and its products mainly include Peginterferon alfa-2b Injection, rhGM-CSF (Recombinant Human Granulocyte/Macrophage Colony-Stimulating Factor for Injection), rHuG-CSF (Recombinant Human Granulocyte-Colony Stimulating Factor for Injection) and Recombinant Human Interleukin-11 for Injection. The firm distributes its products within domestic market and to overseas markets.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 17 Jan 2020
- Employees
- 1,547
- Website
- amoytop.com ↗
Leadership
Pay as last reported
- Mr. Li SunChairman of the Board, General Manager, since 2013CN¥1.3m
- Ms. Yiling YangChief Financial OfficerCN¥957,900
- Mr. Zhili SunDeputy General Manager, Secretary of the BoardCN¥1.1m
- Ms. Liping LaiDeputy General Manager, Director, since 2021CN¥1.0m
- Mr. Fanghe ChenDeputy General ManagerCN¥1.1m
- Ms. Liyu ShiDeputy General ManagerCN¥958,900
- Ms. Meihua YangDeputy General ManagerCN¥1.2m
- Mr. Linzhong ZhangDeputy General ManagerCN¥1.1m
- Mr. Jiehua ZhengDeputy General ManagerCN¥1.2m
- Mr. Weidong ZhouDeputy General ManagerCN¥1.2m
- Mr. Bolin LanDirector
- Mr. Jiahong LiDirectorCN¥120,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Company has a focus on immune-related cytokine drugs for systemic immune solutions.
- Products include Peginterferon alfa-2b Injection and other recombinant human cytokine drugs.
- Employing 1,547 full-time employees with an IPO in 2020.
Weaknesses
- Reliance on domestic market distribution with limited overseas market presence mentioned.
- No specific information on R&D success rates or product approval status provided.
- No details on financial performance or market share are included.
Opportunities
- Potential for expanding overseas market distribution of products.
- Growth in biotechnology sector could increase demand for cytokine drugs.
- Continued R&D in immune-related therapies may lead to new product development.
Threats
- Competition in the biotechnology sector may impact market share.
- Regulatory challenges could affect product approvals and distribution.
- Dependence on a narrow product portfolio may increase vulnerability.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.